In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole study group.

Scientific Claim

Among obese adults with reduced growth hormone secretion receiving tesamorelin treatment, increases in insulin-like growth factor I (IGF-I) levels show a stronger correlation with improvements in phosphocreatine recovery rate (ViPCr; R=0.71; P=0.03) compared to the overall study population.

Original Statement

“The association between IGF-I and PCr recovery was even stronger among subjects treated with tesamorelin only (ViPCr: R=0.71; P=.03).”

From study:The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The claim correctly uses 'correlation' and specifies the subgroup analysis. No causal language is used.

Evidence from Studies

Supporting (1)

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Randomized Controlled Trial

Human

2014 Jan

In people with low growth hormone who took this drug called tesamorelin, their body’s energy recovery improved more closely with rising IGF-I levels than in all participants combined — meaning the drug made this connection stronger.

Contradicting (0)

No contradicting evidence found

Source Study

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Score: 61

DOI: 10.1210/jc.2013-3436

Similar Assertions

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole group of participants.

99%

In people who took tesamorelin, the more their IGF-I levels went up, the better their muscles recovered after exercise — and this link was even stronger than in the whole group.

90%

Taking tesamorelin for a year makes IGF-I levels rise much more in obese people with low growth hormone than taking a dummy pill, with a clear difference between the two groups.

90%

Taking tesamorelin for a year makes the hormone IGF-I go up much more in obese people with low growth hormone compared to taking a sugar pill.

89%

After a year of treatment, tesamorelin didn't show a clear improvement in muscle energy recovery compared to a placebo in obese people with low growth hormone.

88%